What Is Neuronox?

Neuronox is a botulinum toxin type A (BoNT-A) product manufactured by Medytox Inc. in the Republic of Korea. [1]

The Thai product information identifies Neuronox as a purified botulinum toxin type A neurotoxin complex. Published clinical literature has evaluated the Medytox product under terminology including Neuronox, Meditoxin and NBoNT, depending on the study and publication context. [1–5]

These names should not be substituted casually. When reviewing evidence, the terminology used in the original publication should be retained and the relationship explained only where supported by the source.

For example, the 2009 essential-blepharospasm paper explicitly states that Meditoxin is also known as Neuronox. [3]

Who Manufactures Neuronox?

The Thai product information lists Medytox Inc., Republic of Korea as the manufacturer of Neuronox. [1]

For product-specific information—including current presentation, labeled strength, storage, approved indications, contraindications and warnings—the current locally approved product information should take precedence over older publications or general descriptions of BoNT-A.

This distinction matters because scientific publications and regulatory product information answer different questions.

A clinical paper may tell us what happened in a particular study.

The approved product information tells clinicians what is currently authorized for the specific product in the relevant jurisdiction.

What Is in a Neuronox Vial?

According to the Thai product information used for this review, Neuronox contains a botulinum toxin type A purified neurotoxin complex, with excipients including human serum albumin and sodium chloride. [1]

The exact presentation and labeled potency should always be checked against the current local product information.

A formulation description alone does not establish clinical equivalence between botulinum toxin products.

Products that contain the same serotype can still differ in manufacturing processes, formulation, biological potency assays, labeled units and product-specific clinical evidence.

How Does Neuronox Work?

As a BoNT-A product, Neuronox is based on the characteristic pharmacologic mechanism of botulinum neurotoxin type A.

BoNT-A acts predominantly at presynaptic cholinergic nerve terminals. After neuronal binding and internalization, its light chain cleaves SNAP-25, a protein involved in SNARE-dependent synaptic-vesicle fusion.

The result is reduced acetylcholine release and temporary reduction in activation of the targeted muscle. [6–8]

However, mechanism should not be confused with product-specific evidence.

Knowing how BoNT-A works biologically explains the pharmacologic rationale for Neuronox, but does not by itself establish the magnitude of clinical efficacy, duration, safety profile or appropriate dose for a particular indication.

Those questions require clinical evidence involving the actual product.

Does Neuronox Have Product-Specific Clinical Evidence?

Yes.

Published randomized comparative clinical studies have evaluated Neuronox or the same Medytox product identified as Meditoxin in several clinical settings. [2–5]

These include:

• moderate-to-severe glabellar lines;

• essential blepharospasm;

• spastic equinus gait in children with cerebral palsy; and

• post-stroke upper-limb spasticity.

This creates a clinical evidence base across both aesthetic and therapeutic settings.

It does not, however, mean that findings can be pooled into a universal statement of superiority, equivalence, safety or interchangeability.

Each study must be interpreted according to its own population, dose, comparator, endpoint and statistical design.

What Did the Glabellar-Lines Phase III Study Find?

Won and colleagues conducted a randomized, double-blind, active-controlled Phase III study in 314 participants with moderate-to-severe glabellar wrinkles. [2]

Participants were randomized 1:1 to receive 20 U of NBoNT or onabotulinumtoxinA.

The primary endpoint was responder rate according to investigator live assessment at maximum frown at week 4.

At week 4, responder rates were:

NBoNT: 93.7% (133/142)
OnabotulinumtoxinA: 94.5% (138/146)

The prespecified analysis confirmed non-inferiority of NBoNT. The study also reported no serious adverse effects with either toxin. [2]

This is a clinically useful comparative finding, but it must be described correctly:

Non-inferiority does not mean superiority.

It means that, under the study's predefined statistical framework, NBoNT was not unacceptably worse than the comparator by the specified margin.

The publication also disclosed that the study was sponsored by Medytox Inc. and that one author was an employee of Medytox. [2]

That disclosure does not invalidate the study, but it is relevant context when evaluating the evidence.

What Evidence Exists in Essential Blepharospasm?

Yoon, Kim and Lee conducted a double-blind, randomized comparative study of Meditoxin versus Botox in essential blepharospasm. The paper explicitly identifies Meditoxin as another name for Neuronox. [3]

The intention-to-treat population included 60 patients.

The primary efficacy outcome was improvement in severity of spasm four weeks after injection.

Improvement was reported in:

Meditoxin: 90.3%
Botox: 86.2%

The lower bounds of the 95% confidence intervals remained above the prespecified −15% non-inferiority threshold, and the investigators concluded that Meditoxin was non-inferior in both ITT and per-protocol analyses. [3]

Adverse effects were reported in 16.1% and 27.6% of the respective groups, but no serious adverse events were identified in either group.

These percentages should not be converted into a claim that one product is universally safer, because the trial was not evidence of universal safety superiority.

What Evidence Exists in Children With Cerebral Palsy?

Kim and colleagues conducted a randomized, double-blinded, controlled multicentre trial comparing Neuronox with BOTOX for spastic equinus gait in children with cerebral palsy. [4]

Children aged 2–10 years presenting with spastic equinus gait were assessed at three university hospitals.

The study's intention-to-treat analysis included 119 children, with 60 assigned to Neuronox and 59 to BOTOX.

The primary response rates were approximately:

Neuronox: 48.3%
BOTOX: 49.2%

The primary analysis met the trial's prespecified non-inferiority criterion. [4]

This trial provides product-specific evidence in a therapeutic pediatric population. It should not be used to predict aesthetic outcomes because the population, muscles treated, clinical objectives and endpoints are fundamentally different.

What Evidence Exists in Post-Stroke Upper-Limb Spasticity?

A multicenter randomized controlled trial evaluated Neuronox against BOTOX in 196 patients with moderate-to-severe post-stroke upper-limb spasticity. [5]

The primary endpoint was change from baseline in the Modified Ashworth Scale (MAS) at the wrist flexors at week 4.

The mean changes were:

Neuronox: −1.39 ± 0.79
BOTOX: −1.56 ± 0.81

The upper limit of the confidence interval for the between-group difference was 0.40, which remained within the prespecified non-inferiority margin of 0.45. [5]

No significant differences were found in most secondary outcomes or safety measures, with an exception reported for one elbow-flexor MAS comparison at week 12. [5]

Again, the appropriate interpretation is indication- and study-specific non-inferiority—not universal product equivalence.

What Makes the Neuronox Evidence Base Useful?

A useful feature of the Neuronox literature is that the product has been investigated in randomized comparative studies, rather than being described only through general knowledge of the BoNT-A class. [2–5]

That distinction allows several separate questions to be addressed:

Mechanistic evidence: Why should a BoNT-A product reduce neuromuscular transmission?

Product information: What is Neuronox, who manufactures it and how is it presented and labeled?

Clinical evidence: What was actually observed when Neuronox/Meditoxin was studied in defined patient populations?

Keeping these evidence layers separate makes product evaluation more rigorous.

What Does the Evidence Not Prove?

The published trials do not establish that:

• Neuronox is superior to every other BoNT-A product;

• all BoNT-A products are interchangeable;

• the same dose relationship applies across brands and indications;

• results in therapeutic indications predict aesthetic outcomes;

• one clinical trial establishes universal safety;

• a non-inferiority finding means two products are identical.

These distinctions are essential when translating research into clinical or educational content.

How Should Neuronox Be Evaluated?

A scientifically defensible evaluation should ask:

What product was studied?
Who was studied?
What dose and injection protocol were used?
What was the comparator?
What was the primary endpoint?
What was the prespecified statistical question?
What result was observed?
What adverse events were reported?
Who funded the study and were conflicts disclosed?

For Neuronox, this approach is particularly useful because there are multiple randomized comparative studies, but they address different clinical questions. [2–5]

Key Takeaways

Neuronox is a botulinum toxin type A product manufactured by Medytox Inc. in the Republic of Korea. [1]

The product information describes a purified botulinum toxin type A neurotoxin complex with excipients including human serum albumin and sodium chloride. [1]

Beyond the general pharmacology of BoNT-A, Neuronox/Meditoxin has product-specific randomized comparative clinical evidence in glabellar lines, essential blepharospasm, cerebral-palsy-associated spastic equinus and post-stroke upper-limb spasticity. [2–5]

Several of these trials were designed as non-inferiority comparisons and met their prespecified non-inferiority criteria.

The appropriate conclusion is therefore not that Neuronox is universally “better,” but that it has a published product-specific evidence base that can be evaluated study by study.

References

1. NEURONOX (Botulinum toxin Type A) Thai Product Information. Revised April 3, 2023. Medytox Inc., Republic of Korea.

2. Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072.

3. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137. PMID:19794937.

4. Kim K, Shin HI, Kwon BS, Kim SJ, Jung IY, Bang MS. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Dev Med Child Neurol. 2011;53(3):239–244. doi:10.1111/j.1469-8749.2010.03830.x. PMID:21087238.

5. Nam HS, Park YG, Paik NJ, et al. Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS One. 2015;10(6):e0128633. doi:10.1371/journal.pone.0128633. PMID:26030192.

6. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365(6442):160–163. doi:10.1038/365160a0.

7. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006;312(5773):592–596. doi:10.1126/science.1123654.

8. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–235. doi:10.1124/pr.116.012658.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.